YD Bio Limited revenue by segment YDES
Annual
Quarterly
YD Bio Limited splits its revenue into 4 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Sales Of Medical And Other Related Products at $561,817, 94% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2025
Dec 31, 2025
|
|---|---|
| Revenue |
1
|
| Sales Of Medical And Other Related Products |
1
share 94.1%
|
| Contact Lenses |
0
share 5.9%
|
| Nutritional Products |
0
share 0.9%
|
| Supplements |
0
share 0.4%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. More on our methodology.
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- YDES (Nasdaq), YDESW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Taipei City
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 2011674
- Former names
- True Velocity, Inc./DE (until Jun 21, 2024)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.